================================================================================
CLINICAL TRIALS PERFECT MATCHES REPORT (STUDIES WITH PUBLICATIONS AND POSTED RESULTS ONLY)
================================================================================

Patient ID: 3
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G2 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 DOTATOC PET: geringe Speicherung der Leberläsionen.
07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Clinical Question: Weitere Therapie, Everolimus oder PRRT?
Report generated: 2025-07-15 13:23:49

Found 1 relevant clinical trials (with publications and posted results)
--------------------------------------------------------------------------------

1. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
   NCT ID: NCT01524783
   Status: COMPLETED
   Phase: PHASE3
   Perfect Match: YES (Score: 1.0)
   Relevance Reason: 1. **Diagnostic Match:** [Exact match] The study specifically targets advanced Neuroendocrine Tumors (NET) of GI origin, which perfectly aligns with the patient’s diagnosis of a small bowel (Dünndarm) NET. The study inclusion criteria explicitly cover the patient’s primary tumor site. 2. **Tumor Characteristics:** [Grade/stage/biology alignment] The patient has a G2 NET with metastatic disease (lymph node and liver metastases). The study includes patients with advanced NETs, and doesn't exclude ...
   Has Posted Results: YES (verified)
   Condition: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
   Intervention: Everolimus; Placebo; Best suportive care (BSC)
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2012-03-30
   Completion Date: 2020-08-07
   Locations: University of California San Diego - Moores Cancer Center Regulatory, La Jolla, United States; Scripps Clinic Regulatory, La Jolla, United States; Cedars Sinai Medical Center SC, Los Angeles, United States
   URL: https://clinicaltrials.gov/study/NCT01524783
   Summary: The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of c...
   Publications Found: 5
     1. Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S... (N/A)
        PMID: 33560090 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/33560090/
     2. Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle... (N/A)
        PMID: 29081664 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/29081664/
     3. Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Vo... (N/A)
        PMID: 29055056 | Journal: From Clinical Trial Data
        Link: https://pubmed.ncbi.nlm.nih.gov/29055056/
----------------------------------------